Food and Drug Administration (FDA) in 2022
GLP-1RA When compared to GLP-1RA as a class, TZP displayed a lower risk of abdominal discomfort, abdominal pain upper, gastrooesophageal reflux disease, nausea, vomiting, vomiting projectile, pancreatitis, pancreatitis necrotising, thyroid mass and diabetic retinopathy and a greater risk of constipation, eructation and gastrointestinal disorder (Fig
13,7 % Poblacin Comparacin directa en obesidad Pptido Retatrutida Dosis 12 mg/semana Duracin 48 semanas Reduccin de peso ~24,2 % Poblacin Obesidad, sin diabetes Pptido Retatrutida Dosis Dosis mximas Duracin Fase 3 Reduccin de peso ~28,7 % Poblacin Obesidad + osteoartritis Nota importante: Los valores no son directamente comparables porque las poblaciones y los diseos de los estudios difieren
Treatment plans are individualized and monitored over time based on response, tolerance, goals, and health history
East Melbourne, Vic: RACGP, 2020.
Evaluating Whether Short-Term GLP-1 Therapy Fits Your Goals Determining whether short-term semaglutide use is 'effective' depends on what you define as success and whether you commit to maintaining results through behavior change